The making of multispecific immunoglobulins – a clinical perspective [PDF]
MAbsOver the past two decades, bi- and multispecific antibodies have emerged as a rapidly advancing class of therapeutic biologics, transforming oncology and immunotherapy.
Roland Kontermann, Ulrich Brinkmann
exaly +4 more sources
Modular generation of multispecific antibodies using protein trans-splicing [PDF]
MAbsMultispecific antibodies are exhibiting rapid growth in drug development due to their ability to engage multiple therapeutic targets and deliver unique functional properties inaccessible to conventional monoclonal antibodies.
John Bagert, Jared Shadish, Amber Lee
exaly +4 more sources
Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics
Antibodies, 2021 Recombinant protein-based biotherapeutics drugs have transformed clinical pipelines of the biopharmaceutical industry since the launch of recombinant insulin nearly four decades ago. These biologic drugs are structurally more complex than small molecules,
Aaron D'Antona, Zhong Xiaotian
exaly +3 more sources
Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics [PDF]
OncoImmunologyOver the past decades, cancer immunotherapy has evolved into clinical practice, with bispecific T cell engagers (TCEs) and other higher-order multispecific immunotherapeutics emerging as approaches for precision immune modulation.
Enfu Xue +4 more
doaj +2 more sources
Antineutrophil Cytoplasmic Autoantibodies Specific to Bactericidal/Permeability-Increasing Protein: A Cross-Road Between Prolonged Gram-Negative Bacterial Infections and Ulcerative Colitis/Primary Sclerosing Cholangitis [PDF]
DiagnosticsBackground/Objectives: Binding of bactericidal/permeability-increasing (BPI) protein to Gram-negative (GN) bacteria plays a major role in bacterial elimination.
Dragana Jovanovic +7 more
doaj +2 more sources
MAbs, 2020 Monoclonal antibodies (mAbs) are among the fastest growing and most effective therapies for myriad diseases. Multispecific antibodies are an emerging class of novel therapeutics that can target more than one tumor- or immune-associated modulators per ...
Abdullah Kandira +2 more
exaly +3 more sources
Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control. [PDF]
Cancer Rep (Hoboken)ABSTRACT Background Hematologic disorders, including sickle cell disease, anemias, hemoglobinopathies, leukemias, lymphomas, and bleeding disorders, constitute a substantial and growing burden of morbidity and mortality across Africa. Structural health system constraints—limited diagnostic capacity, shortages of trained hematology specialists ...
Obeagu EI.
europepmc +2 more sources
Optimizing colloidal stability and viscosity of multispecific antibodies at the drug discovery-development interface: a systematic predictive case study [PDF]
mAbsThe discovery and development of multispecific antibodies present unique challenges in optimizing their physicochemical properties to enhance developability and manufacturability.
Vanessa Siegmund +8 more
doaj +2 more sources
Developability considerations for bispecific and multispecific antibodies
MAbsBispecific antibodies (bsAb) and multispecific antibodies (msAb) encompass a diverse variety of formats that can concurrently bind multiple epitopes, unlocking mechanisms to address previously difficult-to-treat or incurable diseases. Early assessment of
Alaa Amash +9 more
exaly +3 more sources
Mechanisms of Substrate Recognition by the Multispecific Protein Lysine Methyltransferase SETD6 [PDF]
LifeThe SETD6 protein lysine methyltransferase monomethylates specific lysine residues in a diverse set of substrates which contain the target lysine residue in a highly variable amino acid sequence context.
Gizem T. Ulu +6 more
doaj +2 more sources